Catherine Alix-Panabières, Director of the Human Rare Circulating Cells Laboratory (LCCRH) and University Professor at the University Hospital of Montpellier, shared a post on LinkedIn.
“It was a true honor to take part in the Symposium on Pancreatic Cancer organized by la Fondation ARC near the Château de Vincennes.
I had the opportunity to present our PANLIPSY Project, which aims to develop a Liquid Biopsy approach to detect this extremely aggressive cancer as early as possible. Artificial Intelligence will play a key role to define the right algorithm.
Just a simple blood test could one day enable very early screening and rapid patient care, making a real difference against this deadly disease.
This initiative reflects an exceptional mobilization:
18 research teams are launching ambitious projects, supported by nearly 12 million euros from the BertrandKamal Fund & Fondation ARC pour la recherche sur le cancer.
At the Liquid Biopsy LCCRH Lab – Laboratoire Cellules Circulantes Rares Humaines, CHU de Montpellier, we are proud to be part of this extraordinary scientific and human adventure, enriched by inspiring encounters with the other laureates. Frederic Bard, Richard Tomasini, Patrick Mehlen…
One of the most moving moments was spending time with Bertrand-Kamal’s parents, Annick and Samir, and with Denis Brogniart, who has been deeply involved in this cause for the last years, since Beka left us.
A heartfelt thank you to Fondation ARC pour la recherche sur le cancer for their trust and support.
Together with our collaborators in France and across Europe (PANCAID, Klaus Pantel, Rainer Heuchel, Matthias Löhr), we are putting all our energy into making early detection of pancreatic cancer a reality.”
More from Catherine Alix-Panabières on OncoDaily.
